Sign in
Not yet recruitingNo phase

Remote Monitoring in Young Adults With Inflammatory Joint Disease

Key facts

Who runs it
Diakonhjemmet Hospital
Where
Norway1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
148 people, planned
Starts
Dec 2026
Expected to end
Dec 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Remote digital follow-up
  • Conventional hospital-based follow-up
Record updated
16 November 2026

Who can take part

Age
18 years to 30 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Biological male or female aged 18-30 years at the time of informed consent
  • Clinical diagnosis of JIA, RA, SpA, or PsA
  • Stable DMARD treatment for ≥ 6 months; no initiation, discontinuation, or major dose escalation of a DMARD during the preceding 6 months. Temporary treatment interruptions and minor dose adjustments may be permitted
  • Inactive disease or low disease activity at inclusion, according to diagnosis specific instrument thresholds (JADAS27≤2.7, DAS28≤ 3.2, ASDAS< 2.1, DAPSA≤14)
  • Ability to understand Norwegian
  • Capable of providing written informed consent
  • Access to a smartphone or tablet compatible with installation of the Dignio application

Who cannot take part

  • Major co-morbidities, such as severe malignancies, severe diabetes mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class III or IV), severe respiratory diseases, and/or cirrhosis
  • Indications of active tuberculosis (TB)
  • Stills disease (systemic JIA)
  • Severe psychiatric or mental disorders; current alcohol or other substance abuse; substantial language barriers; or any condition or circumstance that, in the investigator's judgment, would make adherence to the study protocol impossible
  • Abnormal renal function, defined as serum creatinine >142 µmol/L in female and >168 µmol/L in male, or glomerular filtration rate (GFR) <40 mL/min/1.73 m2
  • Abnormal liver function (defined as Alanine Transaminase (ALT) >3x upper normal limit), active or recent hepatitis
  • Pregnant and/or breastfeeding
  • Currently enrolled in a different RCT
  • Leukopenia and/or thrombocytopenia
  • Planned pregnancy during the study period

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 30 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn whether remote follow-up can work as well as regular in-person follow-up at the hospital for young adults with inflammatory joint diseases who have low disease activity. The study includes people aged 18 to 30 years with juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, or spondyloarthritis.

Read full original descriptionShow less

The main questions it aims to answer are:

* Is remote follow-up non-inferior (not worse than) to regular in-person follow-up at the hospital in keeping participants' disease under good control over 24 months? * Is remote follow-up non-inferior to regular in-person follow-up when it comes to disease flare-ups, use of healthcare services, medication use, satisfaction with care, and safety? Researchers will compare a remote follow-up program, with fewer routine outpatient visits, to regular in-person follow-up to see whether disease control after 24 month is non-inferior (not worse)

Participants will:

* Be randomly assigned to either remote digital follow-up or regular in-person follow-up at the hospital . * Complete questionnaires about their symptoms, health, and treatment during the study. * Attend appointments with a rheumatologist at the start of the study and at study end at 24 months. * If assigned to remote follow-up, complete questionnaires every 3 months using a smartphone or tablet application and communicate with a study nurse when needed through secure messaging in the remote monitoring software platform. * If assigned to regular in-person follow-up, attend routine appointments at the rheumatology clinic according to usual practice.

This study aims to determine whether remote follow-up can provide a safe and effective alternative to regular in-person follow-up for young adults with inflammatory joint diseases who have low disease activity .

The 2 groups in the trial

  • Remote digital follow-upTreatment being tested

    Structured remote follow-up for 24 months using the MyDignio digital platform, with electronic triage questionnaires every three months, nurse review of alerts and messages, and scheduled consultations at baseline, 12 and 24 months. Participants continue their prescribed antirheumatic treatment.

  • Conventional hospital-based follow-upExisting treatment, for comparison

    Standard rheumatology outpatient follow-up for 24 months, with scheduled rheumatologist and nurse contacts at baseline, 6, 12, 18 and 24 months. Participants continue their prescribed antirheumatic treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Remote Monitoring and Personalized Patient Pathways in Young Adults With Inflammatory Joint Disease (ReMonit Young)
Criteria questions
Built from NCT07937475, who can take part
Record updated
16 November 2026